Original language | English (US) |
---|---|
Pages (from-to) | 2572-2584 |
Number of pages | 13 |
Journal | Gastroenterology |
Volume | 160 |
Issue number | 7 |
DOIs | |
State | Published - Jun 2021 |
Keywords
- Biomarkers
- Cirrhosis
- Liver Cancer
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. / Singal, Amit G.; Hoshida, Yujin; Pinato, David J. et al.
In: Gastroenterology, Vol. 160, No. 7, 06.2021, p. 2572-2584.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma
AU - Singal, Amit G.
AU - Hoshida, Yujin
AU - Pinato, David J.
AU - Marrero, Jorge A
AU - Nault, Jean Charles
AU - Paradis, Valerie
AU - Tayob, Nabihah
AU - Sherman, Morris
AU - Lim, Young Suk
AU - Feng, Ziding
AU - Lok, Anna S.
AU - Rinaudo, Jo Ann
AU - Srivastava, Sudhir
AU - Llovet, Josep M.
AU - Villanueva, Augusto
N1 - Funding Information: Conflict of interest Amit G. Singal has served as a consultant for Wako Diagnostics, Glycotest, Exact Sciences, Roche, GRAIL, Genentech, Bayer, Eisai, Exelixis, AstraZeneca, BMS, and TARGET Pharmasolutions. Yujin Hoshida has served as advisory board member for Helio Health, consultant for Ferring Pharmaceuticals, research funding from Morphic Therapeutics, and shareholder of Alentis Therapeutics. David J. Pinato received lecture fees from ViiV Healthcare, Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, Astra Zeneca; received research funding (to institution) from MSD, BMS. Jorge Marrero has served as a consultant for Glycotest. Jean-Charles Nault received a research grant from Bayer for Inserm UMR1148. Young Suk Lim is an advisory board member of Bayer Healthcare and Gilead Sciences and received investigator-initiated research funding from Bayer Healthcare and Gilead Sciences. Ziding Feng received research funding from Exact Sciences. Anna S. Lok serves on the advisory board of Epigenomics. Josep Llovet receives research support from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim, Eisai Inc, and Ipsen; and received consulting fees from AstraZeneca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Can-Fite Biopharma, Celsion Corporation, Eli Lilly, Eisai Inc, Exelixis, Genentech, Glycotest, Merck, Nucleix, and Roche. Augusto Villanueva receives consulting fees from Guidepoint, Fujifilm, Boehringer Ingelheim, FirstWord, and MHLife Sciences; advisory board fees from Exact Sciences, Nucleix, Gilead, and NGM Pharmaceuticals; and research support from Eisai. The remaining authors disclose no conflicts. Funding Information: Funding Amit G. Singal’s research is supported in part by National Cancer Institute U01 CA230694 , R01 CA222900 , and U01 CA226052 . Yujin Hoshida’s research is supported by the National Institutes of Health (NIH) ( CA233794 , CA226052 ), European Commission ( ERC-2014-AdG-671231 ), Cancer Prevention and Research Institute of Texas ( RR180016 ). David J. Pinato is supported by the Wellcome Trust Strategic Fund ( PS3416 ), Cancer Research UK (Postdoctoral Bursary Grant C57701/A26137 ), and the Conquer Cancer, the ASCO Foundation (Young Investigator Award 2019) and acknowledges infrastructural support by the Cancer Research UK Imperial Centre and the Experimental Cancer Medicine Centre. Ziding Feng is supported in part by NIH U24CA230144 and U24CA086368. Nabihah Tayob is supported in part by NIH R01CA230503, U24CA230144, R01CA222900, and U01CA230694. Anna S. Lok is supported in part by NIH U01CA230669 and R01CA230503. Josep Llovet. acknowledges funding from the Accelerator Award (CRUCK, AEEC, AIRC) (HUNTER, Ref. C9380/A26813), National Cancer Institute (P30-CA196521), US Department of Defense (CA150272P3), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (PID2019-105378RB-100), and the Generalitat de Catalunya/AGAUR (SGR-1358). Augusto Villanueva is supported by the US Department of Defense (CA150272). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funding agency had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation of the manuscript.
PY - 2021/6
Y1 - 2021/6
KW - Biomarkers
KW - Cirrhosis
KW - Liver Cancer
UR - http://www.scopus.com/inward/record.url?scp=85106905932&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106905932&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2021.01.233
DO - 10.1053/j.gastro.2021.01.233
M3 - Article
C2 - 33705745
AN - SCOPUS:85106905932
VL - 160
SP - 2572
EP - 2584
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 7
ER -